Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy

BJH Dierick, T van der Molen… - Expert review of …, 2020 - Taylor & Francis
BJH Dierick, T van der Molen, BMJ Flokstra-de Blok, A Muraro, MJ Postma, JWH Kocks
Expert review of pharmacoeconomics & outcomes research, 2020Taylor & Francis
Introduction Asthma, allergic rhinitis, atopic dermatitis, and food allergy affect approximately
20% of the global population. Few studies describe the burden of the totality of these
diseases and only a handful studies provide a comprehensive overview of the
socioeconomic impact of these diseases. Areas covered For this narrative review, we
searched Pubmed using selected keywords and inspected relevant references using a
snowballing process. We provide an overview of the socioeconomic burden of allergic …
Introduction
Asthma, allergic rhinitis, atopic dermatitis, and food allergy affect approximately 20% of the global population. Few studies describe the burden of the totality of these diseases and only a handful studies provide a comprehensive overview of the socioeconomic impact of these diseases.
Areas covered
For this narrative review, we searched Pubmed using selected keywords and inspected relevant references using a snowballing process. We provide an overview of the socioeconomic burden of allergic diseases (in particular, asthma, allergic rhinitis, atopic dermatitis, and food allergy). The focus of this review is on their epidemiology (incidence, prevalence), burden (disability-adjusted life years, quality of life), and direct and indirect costs (absenteeism and presenteeism). We have put special emphasis on differences between countries.
Expert commentary
Both the prevalence and the burden of allergic diseases are considerable with prevalence varying between 1% and 20%. We identified a plethora of studies on asthma, but studies were generally difficult to compare due to the heterogeneity in measures used. There were only few studies on the burden of food allergy; therefore, more studies on this allergy are required. For future studies, we recommend standardizing epidemiologic, socioeconomic impact, and quality of life measures of allergic diseases.
Taylor & Francis Online